[HTML][HTML] Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: pre-and postinsulin effects
R Goyal, AF Faizy, SS Siddiqui… - North American journal of …, 2012 - ncbi.nlm.nih.gov
North American journal of medical sciences, 2012•ncbi.nlm.nih.gov
Background: Type 2 diabetes (T2DM) mellitus is a serious implication of obesity. The effect
of insulin therapy on levels of inflammatory markers among obese and non-obese diabetics
has been inadequately studied. Aim: The study aimed to analyze the preinsulin and
postinsulin levels of tumor necrosis factor α (TNF-α) and IL-6 in nonobese and obese T2DM
patients. Materials and Methods: We assessed TNF-α and IL-6 levels in healthy controls (n=
10) and diabetic patients (obese and nonobese; n= 20 each) and analyzed the postinsulin …
of insulin therapy on levels of inflammatory markers among obese and non-obese diabetics
has been inadequately studied. Aim: The study aimed to analyze the preinsulin and
postinsulin levels of tumor necrosis factor α (TNF-α) and IL-6 in nonobese and obese T2DM
patients. Materials and Methods: We assessed TNF-α and IL-6 levels in healthy controls (n=
10) and diabetic patients (obese and nonobese; n= 20 each) and analyzed the postinsulin …
Abstract
Background:
Type 2 diabetes (T2DM) mellitus is a serious implication of obesity. The effect of insulin therapy on levels of inflammatory markers among obese and non-obese diabetics has been inadequately studied.
Aim:
The study aimed to analyze the preinsulin and postinsulin levels of tumor necrosis factor α (TNF-α) and IL-6 in nonobese and obese T2DM patients.
Materials and Methods:
We assessed TNF-α and IL-6 levels in healthy controls (n= 10) and diabetic patients (obese and nonobese; n= 20 each) and analyzed the postinsulin effect on TNF-α and IL-6 levels after 24 and 48 weeks. TNF-α and IL-6 levels were also correlated with fasting plasma glucose of obese and nonobese diabetic patients after insulin therapy.
Results:
There is augmentation of TNF-α and IL-6 levels in diabetic patients and augmentation is more in obese than in nonobese diabetics. The obese group showed a significant decrease (P value< 0.05) after 24 weeks of insulin therapy and an extremely significant decrease (P< 0.001) in TNF-α and IL-6 levels after 48 weeks of therapy. The nonobese group showed an extremely significant decrease (P< 0.001) in TNF-α and IL-6levels after 24 and 48 weeks both.
Conclusion:
There is augmented inflammation in diabetes and it is more in obese diabetics. Insulin therapy tends to counter this inflammation, but the response is delayed in obese diabetics.
ncbi.nlm.nih.gov